Rich is an experienced biotech and pharmaceutical executive with more than 25 years of experience in preclinical, translational and clinical research, primarily in oncology, spanning all aspects of drug discovery and development including biomarker-driven clinical studies.  Prior to joining PIC, Rich was Executive Director at Arvinas, a leading protein degrader platform company, where he led oncology translational strategy for multiple clinical assets from pre-clinical to later-stage clinical development.  Rich has also held senior roles at Celldex, Kolltan Pharmaceuticals, Astellas, OSI Pharmaceuticals, GlaxoSmithKline, and Bayer HealthCare Pharmaceuticals.

“Rich will play a critical role in advancing PIC Therapeutics’ mission to develop differentiated treatments for patients with challenging cancers across a variety of tissues,” said Kathy Bowdish, President and CEO.  “Rich’s Translational Strategy experience will play a pivotal role in advancing our protein translational regulators program to the clinic.  His technical and drug development expertise is of tremendous value as we tackle our first-in-mechanism, first-in-class approach targeting eIF4E with the aim to treat breast cancers and other cancer types.

At PIC Therapeutics, Rich will take a leading role in coordinating company efforts and resources to meet the organization’s translational biology and development milestones including designing and executing early clinical studies.  He will serve on the Executive Leadership Team, providing key insights to shape business goals, indication opportunities and strategy.

“I am thrilled to join PIC’s amazing team,” said Dr. Gedrich. “PIC’s innovative approach to targeting dysregulated protein translation has tremendous potential to benefit patients with aggressive cancers in need of novel therapies. I am eager to work with the team and contribute my experience as PIC transitions into a clinical-stage company.”

About PIC Therapeutics

PIC Therapeutics is a next generation oncology therapeutics company advancing its technology, which targets the protein translational machinery in cancer cells, into a clinical stage therapy.  PIC’s lead drug candidate is a small molecule that targets the translation initiation factor eIF4E, a heretofore undruggable target, and impacts dysregulated proteomes and multiple key cancer drivers in preclinical models with optimal efficacy and tolerability.  The company is developing this innovative first-in-class, first-in-mechanism drug candidate as a potential therapy for a broad range of cancers.  PIC is emerging as a leader in targeted regulation of protein translation and aims to bring hope and possibility to cancer patients worldwide. Headquartered in Natick, MA, to learn more about PIC, please visit www.pictherapeutics.com.

Media Contact

Matt Burke

mattdavidburke@gmail.com